EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation

Area of Science:

• Cell Biology
• Molecular Oncology
• Cancer Research

Background:

• EWI2 is a transmembrane protein from the immunoglobulin superfamily (IgSF) that interacts with tetraspanins and integrins.
• EWI2 influences cell-surface molecule interactions, impacting cancer cell behavior.

Purpose of the Study:

• To investigate the role of EWI2 in regulating cancer cell proliferation, metastasis, and signaling pathways.
• To determine the mechanisms by which EWI2 affects cancer malignancy.

Main Methods:

• EWI2 silencing and ablation in cancer cells.
• In vitro assays for cell movement and proliferation.
• In vivo studies for metastatic potential and malignancy.
• Analysis of epidermal growth factor receptor (EGFR) clustering, endocytosis, and activation.
• Assessment of Erk MAP kinase signaling pathway activity.
• Inhibition of EGFR and Erk kinase.

Main Results:

• EWI2 silencing or ablation led to increased cancer cell movement, proliferation, and metastatic potential.
• These effects were associated with enhanced EGFR clustering, endocytosis, and activation.
• Erk MAP kinase signaling was upregulated upon EWI2 loss.
• Cancer cells exhibited partial epithelial-to-mesenchymal transition (EMT) and faster proliferation.
• Inhibition of EGFR or Erk kinase reversed the pro-cancer phenotypes.

Conclusions:

• EWI2 functions as a tumor suppressor by restraining EGFR activation and downstream signaling.
• EWI2 deficiency promotes cancer progression and metastasis via EGFR and Erk pathways.
• Targeting EGFR or Erk kinase may represent therapeutic strategies for EWI2-deficient cancers.